TRIL - Trillium Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.6025
+0.0275 (+4.78%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.5750
Open0.5749
Bid0.6103 x 1100
Ask0.6100 x 1000
Day's Range0.5640 - 0.6197
52 Week Range0.5150 - 7.0000
Volume1,122,135
Avg. Volume933,870
Market Cap12.577M
Beta (3Y Monthly)2.65
PE Ratio (TTM)N/A
EPS (TTM)-2.5480
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.02
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Trillium Therapeutics Announces Publication Highlighting Activity of TTI-621 in Sézary Syndrome Patients

    TORONTO, April 15, 2019 -- Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer,.

  • GlobeNewswire9 days ago

    Trillium Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

    Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Capital Market, since the closing bid price for the Company’s common shares listed on Nasdaq was below US$1.00 for 30 consecutive trading days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.

  • GlobeNewswire12 days ago

    Trillium Therapeutics to Present at Investor Conferences in April

    TORONTO, April 08, 2019 -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,.

  • GlobeNewswire18 days ago

    Trillium Therapeutics Expands Immuno-Oncology Pipeline With STING Agonist Program

    Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has expanded its immuno-oncology pipeline with a STING agonist program and presented preclinical data from this program at the 2019 Annual Meeting of the American Association for Cancer Research (AACR). STING (stimulator of interferon genes) is an adaptor protein involved in sensing cytosolic DNA that plays a key role in promoting tumor immunity.

  • GlobeNewswire23 days ago

    Trillium Therapeutics to Unveil its STING Agonist Program at the AACR Annual Meeting 2019

    TORONTO, March 27, 2019 -- Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer,.

  • ACCESSWIRE24 days ago

    Four Healthcare Stocks Picking Up Speed on Wednesday

    CORAL GABLES, FL / ACCESSWIRE / March 27, 2019 / The future of the healthcare stock market is directly correlated to whether companies in the healthcare sector have what it takes to meet the growing health challenges facing society. According to recent statistics, global shortages in primary care physicians coupled with rising populations has left millions without access to acute care. Luckily, there are healthcare companies rising to the challenge with innovative medical technologies and nuanced approaches to how we treat and care for our patients.

  • Associated Presslast month

    Trillium: 4Q Earnings Snapshot

    The Mississauga, Ontario-based company said it had a loss of 42 cents per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • GlobeNewswirelast month

    Trillium Therapeutics Reports Annual Financial and Operating Results

    Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the year ended December 31, 2018. Provided an update on the safety and anti-tumor activity observed in the Phase 1 study of local TTI-621 administration in highly pretreated patients with relapsed or refractory mycosis fungoides or Sézary syndrome at the American Society of Hematology 60th Annual Meeting. Continuation monotherapy beyond the initial two week induction period led to further reductions in CAILS scores in 3/4 evaluable patients and evidence of systemic effects were observed in one patient.

  • GlobeNewswirelast month

    Trillium Announces Closing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units

    Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has closed its previously announced underwritten public offering of 6,550,000 common share units (the “Common Share Units”) of the Company and 12,200,000 Series II Non-Voting Convertible First Preferred Share units (the “Series II First Preferred Share Units”) of the Company. The Common Share Units were sold at a public offering price of US$0.80 per Common Share Unit. Each Common Share Unit is comprised of one common share of the Company (each a “Common Share”) and one Common Share purchase warrant (each a “Common Share Warrant”).

  • GlobeNewswire2 months ago

    Trillium Announces Pricing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units

    Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced its previously announced underwritten public offering of 6,550,000 common share units (the “Common Share Units”) of the Company and 12,200,000 Series II Non-Voting Convertible First Preferred Share units (the “Series II First Preferred Share Units”) of the Company (the “Offering”). The Series II First Preferred Share Units are being offered to investors whose purchase of Common Share Units in the Offering may result in such investor, together with its affiliates and certain related parties, beneficially owning more than 4.99% of the Company’s outstanding common shares following the consummation of the Offering.

  • GlobeNewswire2 months ago

    Trillium Announces Proposed Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units

    Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has commenced a public offering of common share units (the “Common Share Units”) of the Company and Series II Non-Voting Convertible First Preferred Share units (the “Series II First Preferred Share Units”) of the Company (the “Offering”).

  • GlobeNewswire5 months ago

    Trillium Therapeutics Provides Update on its Intratumoral TTI-621 Program at the American Society of Hematology 60th Annual Meeting

    Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that new clinical data from the ongoing intratumoral trial of its CD47-blocking agent, TTI-621 (SIRPa-IgG1 Fc), were presented at the American Society of Hematology 60th Annual Meeting, December 1-4, in San Diego, California. “These results build upon the clinical data reported at the EORTC Cutaneous Lymphoma Task Force meeting in September and provide further evidence that intratumoral TTI-621 is well tolerated and biologically active in patients with cutaneous T-cell lymphoma,” said Dr. Niclas Stiernholm, president and CEO of Trillium Therapeutics.

  • GlobeNewswire5 months ago

    Trillium Therapeutics Reports Third Quarter 2018 Financial and Operating Results

    Positive clinical update on the intratumoral trial of TTI-621, a CD47 immune checkpoint inhibitor, presented at the 2018 EORTC CLTF meetingPositive clinical update on the.